President Donald Trump signed the bipartisan Laken Riley Act into law as his administration’s first piece of legislation.

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Eisai and Biogen’s marketing application for Alzheimer’s disease therapy Leqembi will face an independent advisory committee convened by the EMA before a decision is made on approval.

Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Members of the media raise their hands as White House Press Secretary Karoline Leavitt delivers remarks during her first daily briefing, at the White House, in Washington, U.S. January 28, 2025 ...